Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Remicade

Health Plans Enact Coverage Policies for Remicade & Infliximab Biosimilars

From the College  |  February 16, 2018

Several major health plans have recently enacted policies regarding coverage status for Remicade (infliximab) and its biosimilars, Inflectra (infliximab-dyyb) and Renflexis (infliximab-abda). Most of these plans are limiting coverage for the biosimilar products to very specific circumstances. Some have also begun denying claims for biosimilars and instructing patients to switch to Remicade. The plans implementing…

Filed under:Biologics/DMARDsFrom the CollegePractice Support Tagged with:Blue CrossBlue ShieldCigna Corp.Humana Inc.INFLECTRA (infliximab-dyyb)REMICADE (infliximab)Renflexis (infliximab-abda)United Healthcare

U.S. Appeals Court Invalidates J&J Patent on Remicade

Reuters Staff  |  January 24, 2018

(Reuters)—A U.S. appeals court on Tuesday upheld a ruling that invalidated a crucial Johnson & Johnson patent on its blockbuster rheumatoid arthritis drug, Remicade (infliximab), limiting J&J’s ability to seek damages from Pfizer Inc. over its launch of a lower-cost version of the drug. The U.S. Circuit Court of Appeals for the Federal Circuit affirmed…

Filed under:Biologics/DMARDsDrug Updates Tagged with:infliximablawsuitLegalRemicade

Pfizer’s Second Biosimilar of J&J’s Remicade Wins U.S. FDA Approval

Tamara Mathias  |  December 14, 2017

(Reuters)—The U.S. Food and Drug Administration approved Pfizer Inc’s second biosimilar to Johnson & Johnson’s blockbuster rheumatoid arthritis drug, Remicade, the company said on Wednesday. Pfizer’s Ixifi was approved for all eligible indications of Remicade, including the treatment of bowel disease Crohn’s disease and skin disorder plaque psoriasis, the drugmaker said. Biosimilars are medicines deemed…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsJohnson & JohnsonPfizer Inc.Pfizer's IxifiREMICADE (infliximab)

Pfizer Files Suit Against J and J over Remicade Contracts

Caroline Humer  |  September 20, 2017

(Reuters)—Drugmaker Pfizer Inc on Wednesday filed a lawsuit against Johnson and Johnson, saying its rival’s contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer’s new biosimilar. Pfizer said in the suit that Johnson and Johnson is offering discounts on its Remicade treatment in exchange for essentially excluding…

Filed under:Legal Updates Tagged with:Johnson and JohnsonlawsuitPfizer Inc.REMICADE (infliximab)

Celltrion Accelerates U.S. Launch of Infliximab-dyyb, a Remicade Biosimilar

Michele B. Kaufman, PharmD, BCGP  |  September 21, 2016

After winning the initial patent infringement lawsuit filed by Janssen, Celltrion Inc. is now shipping Inflectra (infliximab-dyyb), a biosimilar of Remicade (infliximab), to the U.S…

Filed under:AnalgesicsBiologics/DMARDsDrug Updates Tagged with:BiosimilarsCelltrion Inc.FDAFood and Drug Administrationinfliximabinfliximab-dyybOpioids

Samsung Bioepis Receives Final European Approval for Its Remicade Copy

Reuters Staff  |  June 1, 2016

SEOUL (Reuters)—South Korea’s Samsung Bioepis said on Monday its biosimilar of Johnson & Johnson’s blockbuster rheumatoid arthritis drug Remicade (infliximab) has received final approval from European regulators, paving the way for its second product launch in Europe. Samsung Bioepis, an unlisted arm of South Korea’s top conglomerate Samsung Group, also said last week the biosimilar…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biosimilarsinfliximabinfliximab-dyybInternationalRemicade

Remicade Antibodies Cross-React to Biosimilars

Lorraine L. Janeczko  |  April 6, 2016

NEW YORK (Reuters Health)—Patients with antibodies to infliximab in Remicade should not be switched to biosimilars, researchers warn. “(The) antibodies will cross-react with the new biosimilar drug, potentially reducing clinical response,” Dr. Daniel Nagore, director of research and development at Progenika Biopharma in Derio, Spain, told Reuters Health by email. “The study highlights the importance…

Filed under:Biologics/DMARDsDrug Updates Tagged with:FDAFood and Drug Administrationinfliximabinfliximab-dyyb

FDA Approves Biosimilar to J&J’s Remicade for Multiple Diseases

Reuters Staff  |  April 6, 2016

(Reuters)—The U.S. Food and Drug Administration on Tuesday approved Inflectra, a cheaper version of Johnson & Johnson’s drug Remicade (infliximab), to treat Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriasis and arthritis of the spine. Inflectra, also known as infliximab-dyyb, is expected by some analysts to sell for a 25% discount to Remicade, which generated annual…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsFDAFood and Drug Administrationinfliximabinfliximab-dyyb

FDA Advisory Panel Strongly Backs Biosimilar Form of Remicade

Reuters Staff  |  February 6, 2016

(Reuters)—A medical advisory panel to the U.S. Food and Drug Administration on Tuesday recommended approval of a cheaper biosimilar form of Johnson & Johnson’s arthritis drug Remicade (infliximab) that could eventually batter sales of the branded product. The panel, by a vote of 21-3, supported use of the biosimilar from Celltrion Inc. and Pfizer Inc.,…

Filed under:Axial SpondyloarthritisBiologics/DMARDsDrug Updates Tagged with:Ankylosing SpondylitisCelltrion Inc.FDAFood and Drug Administrationinfliximabmonoclonal antibodyRemsimaRheumatoid Arthritis (RA)

Antibodies to Remicade Cross-React with Biosimilar Remsima

Will Boggs, MD  |  May 28, 2015

NEW YORK (Reuters Health)—Antibodies to infliximab in patients with inflammatory bowel disease (IBD) treated with Janssen’s Remicade cross-react with the biosimilar Remsima from Celltrion (distributed as Inflectra by Hospira in the U.S.), researchers from Israel report. “The cross-reactivity of anti-Remicade antibodies with Remsima attests to shared immune triggering points (epitopes) on these two agents, and…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsCelltrion Inc.infliximabRemsima

  • 1
  • 2
  • 3
  • …
  • 9
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences